Comprehensive Stock Comparison
Compare TG Therapeutics, Inc. (TGTX) vs Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | KNSA | 60.1% revenue growth vs TGTX's 40.8% |
| Value | TGTX | Lower P/E (19.4x vs 34.8x) |
| Quality / Margins | KNSA | 17.5% net margin vs TGTX's 13.3% |
| Stability / Safety | TGTX | Beta 0.43 vs KNSA's 0.46 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KNSA | +119.4% vs TGTX's 0.0% |
| Efficiency (ROA) | KNSA | 15.5% ROA vs TGTX's 8.6%, ROIC 17.1% vs 13.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
TG Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. It generates revenue primarily from sales of its FDA-approved multiple sclerosis drug BRIUMVI (ublituximab) — its first commercial product — with future revenue expected from its pipeline of oncology candidates. The company's competitive advantage lies in its glycoengineered antibody platform technology, which creates potentially more effective and convenient treatments for complex diseases.
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for inflammatory and autoimmune diseases. It generates revenue primarily from sales of ARCALYST for recurrent pericarditis — its only approved product — with additional income from licensing and collaboration agreements. The company's competitive advantage lies in its targeted pipeline of monoclonal antibodies addressing specific immune pathways with high unmet medical needs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KNSA leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). TGTX leads in 1 (Financial Metrics). 1 tied.
Financial Metrics (TTM)
KNSA and TGTX operate at a comparable scale, with $678M and $454M in trailing revenue. Profitability is closely matched — net margins range from 17.5% (KNSA) to 13.3% (TGTX). On growth, TGTX holds the edge at +92.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| RevenueTrailing 12 months | $454M | $678M |
| EBITDAEarnings before interest/tax | $86M | $79M |
| Net IncomeAfter-tax profit | $60M | $119M |
| Free Cash FlowCash after capex | -$59M | $136M |
| Gross MarginGross profit ÷ Revenue | +87.0% | — |
| Operating MarginEBIT ÷ Revenue | +18.9% | +11.4% |
| Net MarginNet income ÷ Revenue | +13.3% | +17.5% |
| FCF MarginFCF ÷ Revenue | -13.0% | +20.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +92.1% | +65.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.9% | +2.5% |
Valuation Metrics
At 59.3x trailing earnings, KNSA trades at a 70% valuation discount to TGTX's 200.6x P/E. On an enterprise value basis, KNSA's 41.0x EV/EBITDA is more attractive than TGTX's 114.4x.
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| Market CapShares × price | $4.8B | $3.4B |
| Enterprise ValueMkt cap + debt − cash | $4.8B | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | 200.60x | 59.32x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.40x | 34.78x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 114.40x | 41.03x |
| Price / SalesMarket cap ÷ Revenue | 14.45x | 5.01x |
| Price / BookPrice ÷ Book value/share | 21.70x | 6.19x |
| Price / FCFMarket cap ÷ FCF | — | 133.57x |
Profitability & Efficiency
TGTX delivers a 21.9% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $21 for KNSA. KNSA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TGTX's 1.14x. On the Piotroski fundamental quality scale (0–9), KNSA scores 6/9 vs TGTX's 3/9, reflecting solid financial health.
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| ROE (TTM)Return on equity | +21.9% | +20.9% |
| ROA (TTM)Return on assets | +8.6% | +15.5% |
| ROICReturn on invested capital | +13.3% | +17.1% |
| ROCEReturn on capital employed | +11.0% | +14.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 1.14x | 0.02x |
| Net DebtTotal debt minus cash | $74M | -$156M |
| Cash & Equiv.Liquid assets | $180M | $166M |
| Total DebtShort + long-term debt | $254M | $9M |
| Interest CoverageEBIT ÷ Interest expense | 3.11x | — |
Total Returns (with DRIP)
A $10,000 investment in KNSA five years ago would be worth $20,324 today (with dividends reinvested), compared to $6,687 for TGTX. Over the past 12 months, KNSA leads with a +119.4% total return vs TGTX's 0.0%. The 3-year compound annual growth rate (CAGR) favors KNSA at 51.2% vs TGTX's 23.4% — a key indicator of consistent wealth creation.
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| YTD ReturnYear-to-date | +2.8% | +5.9% |
| 1-Year ReturnPast 12 months | 0.0% | +119.4% |
| 3-Year ReturnCumulative with dividends | +87.8% | +246.0% |
| 5-Year ReturnCumulative with dividends | -33.1% | +103.2% |
| 10-Year ReturnCumulative with dividends | +261.2% | +128.5% |
| CAGR (3Y)Annualised 3-year return | +23.4% | +51.2% |
Risk & Volatility
TGTX is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than KNSA's 0.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNSA currently trades 90.6% from its 52-week high vs TGTX's 64.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.43x | 0.46x |
| 52-Week HighHighest price in past year | $46.48 | $49.12 |
| 52-Week LowLowest price in past year | $25.28 | $18.26 |
| % of 52W HighCurrent price vs 52-week peak | +64.7% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 58.1 | 47.3 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 469K |
Analyst Outlook
Wall Street rates TGTX as "Buy" and KNSA as "Buy". Consensus price targets imply 64.5% upside for TGTX (target: $50) vs 25.1% for KNSA (target: $56).
| Metric | TGTXTG Therapeutics, … | KNSAKiniksa Pharmaceu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $49.50 | $55.67 |
| # AnalystsCovering analysts | 13 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +0.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| TG Therapeutics, In… (TGTX) | 100 | 208.43 | +108.4% |
| Kiniksa Pharmaceuti… (KNSA) | 100 | 236.47 | +136.5% |
Kiniksa Pharmaceuti… (KNSA) returned +103% over 5 years vs TG Therapeutics, In… (TGTX)'s -33%. A $10,000 investment in KNSA 5 years ago would be worth $20,324 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| TG Therapeutics, In… (TGTX) | $152381.00 | $329M | +215808.8% |
| Kiniksa Pharmaceuti… (KNSA) | $0.00 | $678M | — |
Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $0M (2016) to $678M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| TG Therapeutics, In… (TGTX) | -513.5% | 7.1% | +101.4% |
| Kiniksa Pharmaceuti… (KNSA) | -4.1% | 17.5% | +527.7% |
Chart 4P/E Ratio History — 3 Years
| Stock | 2022 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 5.8 | 55 | +848.3% |
Kiniksa Pharmaceuticals, Ltd. has traded in a 6x–88x P/E range over 3 years; current trailing P/E is ~59x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| TG Therapeutics, In… (TGTX) | -1.6 | 0.15 | +109.4% |
| Kiniksa Pharmaceuti… (KNSA) | -0.74 | 0.75 | +201.4% |
Kiniksa Pharmaceuticals, Ltd.'s EPS grew from $-0.74 (2016) to $0.75 (2025).
Chart 6Free Cash Flow — 5 Years
TG Therapeutics, Inc. generated $-41M FCF in 2024 (+86% vs 2021). Kiniksa Pharmaceuticals, Ltd. generated $25M FCF in 2025 (+117% vs 2021).
TGTX vs KNSA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is TGTX or KNSA a better buy right now?
Kiniksa Pharmaceuticals, Ltd. (KNSA) offers the better valuation at 59.3x trailing P/E (34.8x forward), making it the more compelling value choice. Analysts rate TG Therapeutics, Inc. (TGTX) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TGTX or KNSA?
On trailing P/E, Kiniksa Pharmaceuticals, Ltd. (KNSA) is the cheapest at 59.3x versus TG Therapeutics, Inc. at 200.6x. On forward P/E, TG Therapeutics, Inc. is actually cheaper at 19.4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — TGTX or KNSA?
Over the past 5 years, Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered a total return of +103.2%, compared to -33.1% for TG Therapeutics, Inc. (TGTX). A $10,000 investment in KNSA five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: TGTX returned +261.2% versus KNSA's +128.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TGTX or KNSA?
By beta (market sensitivity over 5 years), TG Therapeutics, Inc. (TGTX) is the lower-risk stock at 0.43β versus Kiniksa Pharmaceuticals, Ltd.'s 0.46β — meaning KNSA is approximately 7% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Kiniksa Pharmaceuticals, Ltd. (KNSA) carries a lower debt/equity ratio of 2% versus 114% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — TGTX or KNSA?
Kiniksa Pharmaceuticals, Ltd. (KNSA) is the more profitable company, earning 17.5% net margin versus 7.1% for TG Therapeutics, Inc. — meaning it keeps 17.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 12.7% versus 11.4% for KNSA. At the gross margin level — before operating expenses — TGTX leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TGTX or KNSA more undervalued right now?
On forward earnings alone, TG Therapeutics, Inc. (TGTX) trades at 19.4x forward P/E versus 34.8x for Kiniksa Pharmaceuticals, Ltd. — 15.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TGTX: 64.5% to $49.50.
07Which pays a better dividend — TGTX or KNSA?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TGTX or KNSA better for a retirement portfolio?
For long-horizon retirement investors, TG Therapeutics, Inc. (TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43), +261.2% 10Y return). Both have compounded well over 10 years (TGTX: +261.2%, KNSA: +128.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TGTX and KNSA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.